摘要
效用结果测量是药物经济学研究中反映健康结果的重要指标之一,对药物经济学的评价结果影响较大。该文从效用指标、效用值测量人群、效用值测量工具、多属性效用量表类型、效用值积分体系以及效用值数据来源这6个方面,分析讨论了典型国家(地区)用于医保目录调整的药物经济学评价证据递交指南中关于效用结果测量的部分,建议中国(除香港、澳门及台湾外)在用于支持医保目录调整的成本-效用分析中使用质量调整生命年作为效用指标,优先使用间接法测量一般人群效用值,并明确不同效用值数据来源的优先级。
Utility measurement is one of the important indicators reflecting health outcomes in pharmacoeconomic evaluation,and it has a large impact on the results of pharmacoeconomic evaluation.This paper analyzed and discussed several considerations of utility measurement defined in guidelines for pharmacoeconomic evidence submission in typical countries(regions),from the six aspects of utility indicators,target populations for utility measurement,utility measurement tools,types of multi-attribute utility instruments,utility value sets and sources of utility data.It was suggested that quality adjusted life years should be used as the utility index in the cost-utility analysis for adjustments of Chinese(except Hong Kong,Macao and Taiwan)medical insurance drug list,and the indirect methods should be used to measure the utility weights for general populations.In addition,the priority of different data sources of utility weights should be clarified.
作者
李海南
雷清强
胡敏
LI Hainan;LEI Qingqiang;HU Min(School of Public Health,Fudan University,Shanghai 200032,China;Center for Research and Evaluation in Pharmacoeconomics,Fudan University,Shanghai 200032,China)
出处
《世界临床药物》
CAS
2022年第6期678-683,共6页
World Clinical Drug
基金
中国经济改革促进与能力加强项目(TCC6)子项目。
关键词
医保目录调整
药物经济学评价
效用
指南
medical insurance drug list adjustment
pharmacoeconomics evalution
utility
guideline
